These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12883091)

  • 1. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.
    Pessina A; Albella B; Bayo M; Bueren J; Brantom P; Casati S; Croera C; Gagliardi G; Foti P; Parchment R; Parent-Massin D; Schoeters G; Sibiril Y; Van Den Heuvel R; Gribaldo L
    Toxicol Sci; 2003 Oct; 75(2):355-67. PubMed ID: 12883091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay.
    Pessina A; Albella B; Bayo M; Bueren J; Brantom P; Casati S; Croera C; Parchment R; Parent-Massin D; Schoeters G; Sibiri Y; Van Den Heuvel R; Gribaldo L
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():75-9. PubMed ID: 12513654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.
    Pessina A; Albella B; Bueren J; Brantom P; Casati S; Gribaldo L; Croera C; Gagliardi G; Foti P; Parchment R; Parent-Massin D; Sibiril Y; Van Den Heuvel R
    Toxicol In Vitro; 2001 Dec; 15(6):729-40. PubMed ID: 11698175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte/macrophage (CFU-GM) assay.
    Masubuchi N
    Pharmazie; 2006 Feb; 61(2):135-9. PubMed ID: 16526561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).
    Gómez SG; Bueren JA; Faircloth G; Albella B
    Toxicol In Vitro; 2003; 17(5-6):671-4. PubMed ID: 14599461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CFU-E/BFU-E and CFU-GM colony growth by cyclophosphamide, 5-fluorouracil and taxol: development of a high-throughput in vitro method.
    Malerba I; Casati S; Diodovich C; Parent-Massin D; Gribaldo L
    Toxicol In Vitro; 2004 Jun; 18(3):293-300. PubMed ID: 15046776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs.
    Pessina A; Parent-Massin D; Albella B; Van Den Heuvel R; Casati S; Croera C; Malerba I; Sibiril Y; Gomez S; de Smedt A; Gribaldo L
    Toxicol In Vitro; 2009 Feb; 23(1):194-200. PubMed ID: 19084588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro sensitivity of granulo-monocytic progenitors as a new toxicological cell system and endpoint in the ACuteTox Project.
    Cerrato L; Valeri A; Bueren JA; Albella B
    Toxicol Appl Pharmacol; 2009 Jul; 238(2):111-9. PubMed ID: 19442680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.
    Masubuchi N; May RD; Atsumi R
    Clin Cancer Res; 2004 Oct; 10(19):6722-31. PubMed ID: 15475463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay.
    Rich IN; Hall KM
    Toxicol Sci; 2005 Oct; 87(2):427-41. PubMed ID: 16002476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.
    O'Brien PJ; Irwin W; Diaz D; Howard-Cofield E; Krejsa CM; Slaughter MR; Gao B; Kaludercic N; Angeline A; Bernardi P; Brain P; Hougham C
    Arch Toxicol; 2006 Sep; 80(9):580-604. PubMed ID: 16598496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing.
    Haglund C; Aleskog A; Håkansson LD; Höglund M; Jacobsson S; Larsson R; Lindhagen E
    Toxicol Lett; 2010 May; 194(3):102-7. PubMed ID: 20167269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFU-GM assay for evaluation of drug myelotoxic activity.
    Pessina A; Bonomi A
    Curr Protoc Toxicol; 2007 Nov; Chapter 20():Unit20.2. PubMed ID: 23045143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The opposing actions in vivo on murine myelopoiesis of purified preparations of lactoferrin and the colony stimulating factors.
    Broxmeyer HE; Williams DE; Hangoc G; Cooper S; Gentile P; Shen RN; Ralph P; Gillis S; Bicknell DC
    Blood Cells; 1987; 13(1-2):31-48. PubMed ID: 3499193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal responses of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor in human cyclic neutropenia.
    Wright DG; LaRussa VF; Salvado AJ; Knight RD
    J Clin Invest; 1989 Apr; 83(4):1414-8. PubMed ID: 2649515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models for evaluating the myelosuppressive effects of cancer chemotherapeutic agents.
    Schurig JE; Schlein A; Florczyk AP; Farwell AR; Bradner WT
    Exp Hematol; 1985; 13 Suppl 16():101-5. PubMed ID: 3987834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.